According to the Wall Street Journal, the shortage of critical cancer drugs is getting worse. The U.S. government’s measures to mitigate this problem have failed because it has ignored NCPA’s conclusion that shortages result from too much, not too little control over the market for these drugs.
The government keeps tightening the screws on manufacturers, and the shortages keep growing. See Devon Herrick’s testimony to the U.S. Senate in 2011 and my own study published in 2012.
Read the entire entry at NCPA's Health Policy Blog.